<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3182</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3182</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РАЗНОЕ</subject></subj-group></article-categories><title-group><article-title>Дисфункция правого желудочка на фоне противоопухолевого лечения у пациенток с раком молочной железы</article-title><trans-title-group xml:lang="en"><trans-title>Right ventricular dysfunction during chemotherapy in patients with breast cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0963-4793</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сумин</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sumin</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Николаевич Сумин — доктор медицинских наук, зав. лабораторией коморбидности при сердечно-сосудистых заболеваниях отдела клинической кардиологии.</p><p>Кемерово, Сосновый бульвар, 6</p></bio><bio xml:lang="en"><p>Head of the Laboratory of Comorbidity of Cardiovascular Diseases, Department of Clinical Cardiology.</p><p>Kemerovo</p></bio><email xlink:type="simple">sumian@kemcardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7367-2620</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слепынина</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Slepynina</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлия Сергеевна Слепынина — кандидат медицинских наук, научный сотрудниклаборатории лучевых методов диагностики отдела клинической кардиологии.</p><p>650002, Кемерово, Сосновый бульвар, 6</p></bio><bio xml:lang="en"><p>Ph.D, Researcher at the Laboratory of Diagnostic Radiology, Department of Clinical Cardiology.</p><p>Kemerovo</p></bio><email xlink:type="simple">usslep@kemcardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4108-164X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щеглова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcheglova</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Викторовна Щеглова — кандидат медицинских наук, научный сотрудниклаборатории коморбидности при сердечно-сосудистых заболеваниях отдела клинической кардиологии.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Ph.D, Researcher at the Laboratory of Comorbidity of Cardiovascular Diseases, Department of Clinical Cardiology.</p><p>Kemerovo</p></bio><email xlink:type="simple">nura.karpovitch@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7993-5789</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Валерьевна Иванова — научный сотрудник лаборатории коморбидности при сердечно-сосудистых заболеваниях отдела клинической кардиологии.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Researcher at the Laboratory of Comorbidity of Cardiovascular Diseases, Department of Clinical Cardiology.</p><p>Kemerovo</p></bio><email xlink:type="simple">anna.oritn@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7458-6962</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поликутина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Polikutina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Михайловна Поликутина — доктор медицинских наук, ведущий научный сотрудник лаборатории лучевых методов диагностики отдела клинической кардиологии.</p><p>650002, Тел.: +7 (905) 900-20-55</p></bio><bio xml:lang="en"><p>Ph.D, Leading Researcher at the Laboratory of Diagnostic Radiology, Department of Clinical Cardiology.</p><p>Kemerovo</p></bio><email xlink:type="simple">poliom@kemcardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>06</month><year>2022</year></pub-date><volume>21</volume><issue>5</issue><fpage>3182</fpage><lpage>3182</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сумин А.Н., Слепынина Ю.С., Щеглова А.В., Иванова А.В., Поликутина О.М., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Сумин А.Н., Слепынина Ю.С., Щеглова А.В., Иванова А.В., Поликутина О.М.</copyright-holder><copyright-holder xml:lang="en">Sumin A.N., Slepynina Y.S., Shcheglova А.V., Ivanova A.V., Polikutina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3182">https://cardiovascular.elpub.ru/jour/article/view/3182</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить состояние правого желудочка (ПЖ) на фоне химиотерапии (ХТ) у пациенток с раком молочной железы (РМЖ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 40 женщин 35-72 лет с РМЖ, которым проводилась ХТ антрациклинами. Основная группа (n=40) — женщины с РМЖ, обследованные при первичном контакте; 37 человек основной группы повторно обследованы через 6 мес.; контрольная группа (n=25) — женщины без РМЖ в анамнезе.</p></sec><sec><title>Результаты</title><p>Результаты. В основной группе срединный поперечный размер и толщина передней стенки ПЖ были значимо больше, чем в группе контроля (р&lt;0,001). Уровень скорости раннего диастолического транстрикуспидального потока (Еt) в динамике через 6 мес. оказался ниже, чем в контрольной группе (р=0,003). Соотношение Еt и позднего (Аt) диастолического транстрикуспидального потока (Еt/Аt) у пациенток с РМЖ значимо снизилось за время наблюдения (р&lt;0,05) при сравнении с контрольной группой и исходными значениями. Отмечены бóльшие значения индекса Tei в основной группе по сравнению с контрольной (р&lt;0,05). При логистической регрессии для индекса Tei в модель вошли лучевая терапия, суммарная доза антрациклинов и баллы по шкале негативной возбудимости: F(3,17)=12,548, p&lt;0,001, R2=0,729. Для отношения Еt/ Аt значимыми факторами были дополнительное проведение лучевой терапии и частота сердечных сокращений: F(2,16)=12,548, p=0,005, R2=0,526.</p></sec><sec><title>Заключение</title><p>Заключение. На фоне ХТ отмечено ухудшение систолической (увеличение индекса Tei, увеличение объемов ПЖ) и диастолической (снижение показателя Еt и отношения Еt/Аt) функции ПЖ. Ключевые слова: дисфункция правого желудочка, противоопухолевая терапия, рак молочной железы, антрациклины.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess the right ventricle (RV) during chemotherapy (CT) in patients with breast cancer (BC).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 40 women aged 35-72 years with BC who underwent anthracycline chemotherapy. The main group (n=40) included women with BC, examined at the first contact, 37 of whom were reexamined after 6 months. Control group (n=25) included women without BC.</p></sec><sec><title>Results</title><p>Results. In the main group, the median transverse dimension and anterior wall thickness of the RV were significantly greater than in the control group (p&lt;0,001). Early diastolic transtricuspid flow velocity (Et) after 6 months was lower than in the control group (p=0,003). The ratio of Et to late (At) diastolic transtricuspid flow (Et/At) in BC patients significantly decreased during the follow-up period (p&lt;0,05) when compared with the control group and baseline values. Higher values of Tei index were noted in the main group compared to the control one (p&lt;0,05). Using logistic regression for the Tei index, the model included radiation therapy, the total anthracycline dose, and negative affectivity score as follows: F(3,17)=12,548, p&lt;0,001, R2=0,729. For the Et/At ratio, additional radiation therapy and heart rate were significant factors as follows: F(2,16)=12,548, p=0,005, R2=0,526.</p></sec><sec><title>Conclusion</title><p>Conclusion. Against the background of CT, deterioration of RV systolic (increase in Tei index and RV volume) and diastolic (decrease in Et and Et/At ratio) function was noted.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>дисфункция правого желудочка</kwd><kwd>противоопухолевая терапия</kwd><kwd>рак молочной железы</kwd><kwd>антрациклины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>right ventricular dysfunction</kwd><kwd>anticancer therapy</kwd><kwd>breast cancer</kwd><kwd>anthracyclines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801. doi:10.1093/eurheartj/ehw211.</mixed-citation><mixed-citation xml:lang="en">Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801. doi:10.1093/eurheartj/ehw211.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Biersmith MA, Tong MS, Guha A, et al. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. J Am Heart Assoc. 2020;9(2):e013755. doi:10.1161/JAHA.119.013755.</mixed-citation><mixed-citation xml:lang="en">Biersmith MA, Tong MS, Guha A, et al. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. J Am Heart Assoc. 2020;9(2):e013755. doi:10.1161/JAHA.119.013755.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lenneman CG, Sawyer DB. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circulation Research. 2016;118:1008-20. doi:10.1161/circresaha.115.303633.</mixed-citation><mixed-citation xml:lang="en">Lenneman CG, Sawyer DB. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circulation Research. 2016;118:1008-20. doi:10.1161/circresaha.115.303633.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cherata DA, Donoiu I, Diaconu R, et al. Longitudinal strain analysis allows the identification of subclinical deterioration of right ventricular function in patients with cancer therapy-related left ventricular dysfunction. Discoveries (Craiova). 2019;7(2):e94. doi:10.15190/d.2019.7.</mixed-citation><mixed-citation xml:lang="en">Cherata DA, Donoiu I, Diaconu R, et al. Longitudinal strain analysis allows the identification of subclinical deterioration of right ventricular function in patients with cancer therapy-related left ventricular dysfunction. Discoveries (Craiova). 2019;7(2):e94. doi:10.15190/d.2019.7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Planek MIC, Manshad A, Hein K, et al. Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction. Cardiooncology. 2020;6:10. doi:10.1186/s40959020-00066-8.</mixed-citation><mixed-citation xml:lang="en">Planek MIC, Manshad A, Hein K, et al. Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction. Cardiooncology. 2020;6:10. doi:10.1186/s40959020-00066-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao R, Shu F, Zhang C, et al. Early detection and prediction of Anthracycline-induced right ventricular Cardiotoxicity by 3-dimensional echocardiography. JACC: CardioOncology. 2020;2(1):13-22. doi:10.1016/j.jaccao.2020.01.007.</mixed-citation><mixed-citation xml:lang="en">Zhao R, Shu F, Zhang C, et al. Early detection and prediction of Anthracycline-induced right ventricular Cardiotoxicity by 3-dimensional echocardiography. JACC: CardioOncology. 2020;2(1):13-22. doi:10.1016/j.jaccao.2020.01.007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tadic M, Cuspidi C, Bombelli M, et al. Right heart remodeling induced by arterial hypertension: Could strain assessment be helpful? J Clin Hypertens (Greenwich). 2018;20(2):400-7. doi:10.1111/jch.13186.</mixed-citation><mixed-citation xml:lang="en">Tadic M, Cuspidi C, Bombelli M, et al. Right heart remodeling induced by arterial hypertension: Could strain assessment be helpful? J Clin Hypertens (Greenwich). 2018;20(2):400-7. doi:10.1111/jch.13186.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Surkova E, Muraru D, Genovese D, et al. Relative Prognostic Importance of Left and Right Ventricular Ejection Fraction in Patients With Cardiac Diseases. J Am Soc Echocardiogr. 2019;32(11):1407-15. doi:10.1016/j.echo.2019.06.009.</mixed-citation><mixed-citation xml:lang="en">Surkova E, Muraru D, Genovese D, et al. Relative Prognostic Importance of Left and Right Ventricular Ejection Fraction in Patients With Cardiac Diseases. J Am Soc Echocardiogr. 2019;32(11):1407-15. doi:10.1016/j.echo.2019.06.009.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sumin AN, Korok EV, Sergeeva TJ. Preexisting Right Ventricular Diastolic Dysfunction and Postoperative Cardiac Complications in Patients Undergoing Nonemergency Coronary Artery Bypass Surgery. J Cardiothorac Vasc Anesth. 2021;35(3):799-806. doi:10.1053/j.jvca.2020.09.100.</mixed-citation><mixed-citation xml:lang="en">Sumin AN, Korok EV, Sergeeva TJ. Preexisting Right Ventricular Diastolic Dysfunction and Postoperative Cardiac Complications in Patients Undergoing Nonemergency Coronary Artery Bypass Surgery. J Cardiothorac Vasc Anesth. 2021;35(3):799-806. doi:10.1053/j.jvca.2020.09.100.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tello K, Seeger W, Naeije R, et al. Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. Br J Pharmacol. 2021;178:90107. doi:10.1111/bph.14866.</mixed-citation><mixed-citation xml:lang="en">Tello K, Seeger W, Naeije R, et al. Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. Br J Pharmacol. 2021;178:90107. doi:10.1111/bph.14866.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Amsallem M, Mercier O, Kobayashi Y, et al. Forgotten No More: A Focused Update on the Right Ventricle in Cardiovascular Disease. JACC Heart Fail. 2018;6(11):891-903. doi:10.1016/j.jchf.2018.05.022.</mixed-citation><mixed-citation xml:lang="en">Amsallem M, Mercier O, Kobayashi Y, et al. Forgotten No More: A Focused Update on the Right Ventricle in Cardiovascular Disease. JACC Heart Fail. 2018;6(11):891-903. doi:10.1016/j.jchf.2018.05.022.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tadic M, Cuspidi C, Hering D, et al. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017;40(7):437-43. doi:10.1002/clc.22672.</mixed-citation><mixed-citation xml:lang="en">Tadic M, Cuspidi C, Hering D, et al. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017;40(7):437-43. doi:10.1002/clc.22672.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Гендлин Г. Е., Емелина Е. И., Никитин И. Г. и др. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017;3(143):145-54. doi:10.15829/1560-4071-2017-3-145-154.</mixed-citation><mixed-citation xml:lang="en">Gendlin GE, Emelina ЕI, Nikitin IG, et al. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Russian Journal of Cardiology. 2017;(3):14554. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Аншелес А. А., Сергиенко И. В., Прус Ю. А. и др. Радионуклидная диагностика кардиотоксичности, индуцированной химиотерапией. Кардиоваскулярная терапия и профилактика. 2021;20(2):2537. doi:10.15829/1728-8800-2021-2537.</mixed-citation><mixed-citation xml:lang="en">Ansheles AA, Sergienko IV, Prus YuA, et al. Nuclear imaging of chemotherapy-induced cardiotoxicity. Cardiovascular Therapy and Prevention. 2021;20(2):2537. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Raykh OI, Sumin AN, Korok EV. The Influence of Personality Type D on Cardiovascular Prognosis in Patients After Coronary Artery Bypass Grafting: Data from a 5-Year-Follow-up Study. Int J Behav Med. 2022;29(1):46-56. doi:10.1007/s12529-021-09992-y.</mixed-citation><mixed-citation xml:lang="en">Raykh OI, Sumin AN, Korok EV. The Influence of Personality Type D on Cardiovascular Prognosis in Patients After Coronary Artery Bypass Grafting: Data from a 5-Year-Follow-up Study. Int J Behav Med. 2022;29(1):46-56. doi:10.1007/s12529-021-09992-y.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kessing D, Denollet J, Widdershoven J, Kupper N. Self-care and health-related quality of life in chronic heart failure: A longitudinal analysis. Eur J Cardiovasc Nurs. 2017;16(7):605-13. doi:10.1177/1474515117702021.</mixed-citation><mixed-citation xml:lang="en">Kessing D, Denollet J, Widdershoven J, Kupper N. Self-care and health-related quality of life in chronic heart failure: A longitudinal analysis. Eur J Cardiovasc Nurs. 2017;16(7):605-13. doi:10.1177/1474515117702021.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SR, Nho JH, Nam JH. Relationships among Type-D personality, symptoms and quality of life in patients with ovarian cancer receiving chemotherapy. J Psychosom Obstet Gynaecol. 2018;39(4):289-96. doi:10.1080/0167482X.2017.1372416.</mixed-citation><mixed-citation xml:lang="en">Kim SR, Nho JH, Nam JH. Relationships among Type-D personality, symptoms and quality of life in patients with ovarian cancer receiving chemotherapy. J Psychosom Obstet Gynaecol. 2018;39(4):289-96. doi:10.1080/0167482X.2017.1372416.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SR, Nho JH, Kim HY, et al. Type-D personality and quality of life in patients with primary brain tumours. Eur J Cancer Care (Engl). 2021;30(2):e13371. doi:10.1111/ecc.13371.</mixed-citation><mixed-citation xml:lang="en">Kim SR, Nho JH, Kim HY, et al. Type-D personality and quality of life in patients with primary brain tumours. Eur J Cancer Care (Engl). 2021;30(2):e13371. doi:10.1111/ecc.13371.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67(1):89-97. doi:10.1097/01.psy.0000149256.81953.49.</mixed-citation><mixed-citation xml:lang="en">Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67(1):89-97. doi:10.1097/01.psy.0000149256.81953.49.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Barthur A, Brezden-Masley C, Connelly KA, et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19(1):44. doi:10.1186/s12968017-0356-4.</mixed-citation><mixed-citation xml:lang="en">Barthur A, Brezden-Masley C, Connelly KA, et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19(1):44. doi:10.1186/s12968017-0356-4.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">de Souza TF, Silva TQ, Antunes-Correa L, et al. Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy. Sci Rep. 2021;11(1):17132. doi:10.1038/s41598-021-96630-y.</mixed-citation><mixed-citation xml:lang="en">de Souza TF, Silva TQ, Antunes-Correa L, et al. Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy. Sci Rep. 2021;11(1):17132. doi:10.1038/s41598-021-96630-y.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Miao Y, Zhang W, Zhongi Y, et al. Diastolic function of the right ventricle is impaired in experimental type 2 diabetic rat models. Turk J Med Sci. 2014;44:448-53. doi:10.3906/SAG-1212-12.</mixed-citation><mixed-citation xml:lang="en">Miao Y, Zhang W, Zhongi Y, et al. Diastolic function of the right ventricle is impaired in experimental type 2 diabetic rat models. Turk J Med Sci. 2014;44:448-53. doi:10.3906/SAG-1212-12.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Murch SD, La Gerche A, Roberts TJ, et al. Abnormal right ventricular relaxation in pulmonary hypertension. Pulm Circ. 2015;5:370-5. doi:10.1086/681268.</mixed-citation><mixed-citation xml:lang="en">Murch SD, La Gerche A, Roberts TJ, et al. Abnormal right ventricular relaxation in pulmonary hypertension. Pulm Circ. 2015;5:370-5. doi:10.1086/681268.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sumin AN, Korok EV, Sergeeva TY. Impaired right ventricular filling in patients with a chronic coronary syndrome. Med Ultrason. 2021;23(3). doi:10.11152/mu-2747.</mixed-citation><mixed-citation xml:lang="en">Sumin AN, Korok EV, Sergeeva TY. Impaired right ventricular filling in patients with a chronic coronary syndrome. Med Ultrason. 2021;23(3). doi:10.11152/mu-2747.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider M, Aschauer S, Mascherbauer J, et al. Echocardiographic assessment of right ventricular function: current clinical practice. Int J Cardiovasc Imaging. 2019;35(1):49-56. doi:10.1007/s10554-018-1428-8.</mixed-citation><mixed-citation xml:lang="en">Schneider M, Aschauer S, Mascherbauer J, et al. Echocardiographic assessment of right ventricular function: current clinical practice. Int J Cardiovasc Imaging. 2019;35(1):49-56. doi:10.1007/s10554-018-1428-8.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">de Mol M, Visser S, Aerts J, et al. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study. BMC Cancer. 2020;20(1):431. doi:10.1186/s12885020-06823-3.</mixed-citation><mixed-citation xml:lang="en">de Mol M, Visser S, Aerts J, et al. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study. BMC Cancer. 2020;20(1):431. doi:10.1186/s12885020-06823-3.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
